DueDiligence
ExploreSearchAbout
DXCM·NasdaqGS·Healthcare

DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

$75.37
↑0.12(0.16%)
Market cap $29.1B
Revenue
$4.7B
↑ 15.6% YoY
Net Income
$836.3M
↑ 45.1% YoY
Gross Profit
—

Generating analysis for DexCom, Inc.… this takes ~10 seconds the first time.

Compare
Related companies
ABTAbbottMDTMedtronicTXNTexas InstrumentsQCOMQualcomm

Deep Dive

Member

A full investor briefing on DexCom, Inc. — history, leadership, risks, and outlook.